-+ 0.00%
-+ 0.00%
-+ 0.00%

Pulse Biosciences Q1 FY26 net loss widens to $18.6 million; revenue rises to $401,000

PUBT·05/04/2026 11:01:44
Listen to the news
Pulse Biosciences Q1 FY26 net loss widens to $18.6 million; revenue rises to $401,000
  • Pulse Biosciences posted Q1 GAAP net loss of USD 18.6 million, widening from USD 16.8 million a year earlier; net loss per share widened to USD 0.27 from USD 0.25.
  • Revenue rose to USD 401,000 from no revenue a year earlier.
  • Total GAAP costs and expenses increased to USD 19.6 million from USD 18.0 million, due to increased investment in clinical programs, partially offset by lower stock-based compensation expense.
  • Cash and cash equivalents fell to USD 68.3 million as of March 31, 2026 from USD 80.7 million at Dec. 31, 2025; cash used in operating activities totaled USD 14.6 million.
  • Started enrollment in NANOPULSE-AF, a U.S. IDE pivotal trial for endocardial catheter AF ablation, with enrollment now expected to complete in early Q4 2026; continued progress on NANOCLAMP-AF with enrollment expected to complete by end of first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605040700BIZWIRE_USPR_____20260504_BW698797) on May 04, 2026, and is solely responsible for the information contained therein.